Related Experiment Video
Updated: Jun 17, 2026
07:15
A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies
Published on: July 28, 2020
Validation of potential therapeutic targets in alveolar soft part sarcoma: an immunohistochemical study utilizing
Alexander J Lazar1, Guy Lahat, Sarah E Myers
1Department of Pathology, The University of Texas M. D. Anderson Cancer Center, Sarcoma Research Center, Houston, TX 77030-4009, USA. alazar@mdanderson.com
Histopathology
|December 17, 2009
Summary
Alveolar soft part sarcoma (ASPS) therapies are lacking. This study found activated c-Met signaling and increased angiogenic factors in ASPS tumors, suggesting new therapeutic targets.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Alveolar soft part sarcoma (ASPS) is characterized by a specific translocation, der(17)t(X;17)(p11.2;q25), creating the ASPSCR1-TFE3 fusion gene.
- Current therapeutic options for advanced ASPS are limited, highlighting the need for novel treatment strategies.
Purpose of the Study:
- To investigate the expression of potential molecular therapeutic targets in ASPS tumor samples.
- To evaluate the activation status of key signaling pathways implicated in cancer progression.
Main Methods:
- Immunohistochemical analysis was performed on a tissue microarray from 26 ASPS tumors.
- Expression levels of hepatocyte growth factor, c-Met, phosphorylated c-Met, AKT, MEK, EGFR, VEGF, p53, and vimentin were assessed.
Main Results:
- Activated c-Met signaling and phosphorylation of downstream effectors (AKT, MEK) were observed.
- Vascular endothelial growth factor (VEGF) showed variable expression, suggesting an angiogenic phenotype.
- Limited epidermal growth factor receptor (EGFR) expression and minimal p53 and vimentin expression were noted.
Conclusions:
- The findings validate an intact signaling cascade, likely driven by the ASPSCR1-TFE3 fusion, in ASPS.
- Targeting activated c-Met and angiogenic pathways may represent promising therapeutic strategies for ASPS.
- Combination therapies targeting both tumor cells and angiogenesis warrant further investigation.
